Asset Management One Co. Ltd. Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Asset Management One Co. Ltd. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 253,355 shares of the medical device company’s stock after purchasing an additional 9,980 shares during the quarter. Asset Management One Co. Ltd. owned approximately 0.06% of DexCom worth $17,302,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DXCM. Oppenheimer & Co. Inc. increased its holdings in DexCom by 4.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical device company’s stock worth $1,449,000 after acquiring an additional 974 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in DexCom by 65.5% in the 1st quarter. Flagship Harbor Advisors LLC now owns 9,667 shares of the medical device company’s stock worth $660,000 after acquiring an additional 3,825 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in DexCom in the 1st quarter worth about $775,000. Intact Investment Management Inc. increased its holdings in DexCom by 66.7% in the 1st quarter. Intact Investment Management Inc. now owns 20,000 shares of the medical device company’s stock worth $1,366,000 after acquiring an additional 8,000 shares during the last quarter. Finally, First American Bank increased its holdings in DexCom by 2.8% in the 1st quarter. First American Bank now owns 26,988 shares of the medical device company’s stock worth $1,843,000 after acquiring an additional 725 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ:DXCM opened at $84.68 on Thursday. The company has a market capitalization of $33.20 billion, a price-to-earnings ratio of 63.19, a PEG ratio of 1.87 and a beta of 1.46. The business has a 50 day moving average of $81.02 and a 200 day moving average of $79.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.19.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares of the company’s stock, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director now directly owns 56,621 shares in the company, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,724 shares of company stock worth $2,157,034 in the last three months. 0.32% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Truist Financial assumed coverage on DexCom in a report on Monday, June 16th. They issued a “buy” rating and a $102.00 price objective for the company. Citigroup reissued a “buy” rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They issued a “buy” rating and a $104.00 target price for the company. Mizuho initiated coverage on DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price for the company. Finally, Piper Sandler cut their target price on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.